Table 1 Number and proportion of plasma cell disorder patients and healthy donors with protective serum IgG antibody levels against bacterial antigens.

From: Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms

n (%)

PCD n = 62

MGUS n = 10

SMM n = 15

Active MM n = 21

MM remission n = 16

HC n = 40

Pn1

9 (15)***

2 (20)

3 (20)

3 (14)

1 (6)

19 (48)

Pn3

3 (5)**

1 (10)

0

1 (5)

1 (6)

10 (25)

Pn4

10 (16)

2 (20)

5 (33)

1 (5)

2 (13)

6 (15)

Pn5

18 (29)**

6 (60)

5 (33)

4 (19)

3 (19)

23 (58)

Pn6B

12 (19)

2 (20)

3 (20)

4 (19)

3 (19)

14 (35)

Pn7F

24 (39)

3 (30)

8 (53)

6 (29)

7 (44)

22 (55)

Pn9V

16 (26)

5 (50)

6 (40)

4 (19)

1 (6)

15 (38)

Pn14

35 (57)***

8 (80)

7 (47)

11 (52)

9 (56)

35 (88)

Pn18C

22 (36)***

5 (50)

7 (47)

7 (33)

3 (19)

30 (75)

Pn19A

23 (37)*

6 (60)

8 (53)

4 (19)

5 (31)

23 (58)

Pn19F

19 (31)

2 (20)

6 (40)

5 (24)

6 (38)

23 (58)

Pn23F

13 (21)*

4 (40)

3 (20)

3 (14)

3 (19)

17 (43)

8/12 serotypes with protective level

6 (10)***

1 (10)

3 (20)

1 (5)

1 (6)

16 (40)

  1. Protection classed according to WHO cut-off of ≥0.35 μg/ml. Significance of PCD vs HC cohort indicated by ***p < .001, **p < .01, *p < .05, analysed using Chi Square. PCD plasma cell disorder cohort, MGUS monoclonal gammopathy of undetermined significance, SMM smouldering multiple myeloma, MM multiple myeloma, HC healthy control cohort, Pn pneumococcal.
Back to article page